Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


SpectraMax® i3: When is the last time you inspected your cells and ran an assay on the same instrument?

Product Image
Product Description

The SpectraMax® i3 is Molecular Devices latest multi-mode microplate reader which delivers several applications including; Ultra-Violet to visible absorbance detection, fluorescence intensity and multi-colour luminescence. There is the option to add user-installable cartridges as your research needs evolve including HTRF®, AlphaScreen® and Fluorescence Polarisation assays as well as cellular imaging, (with the SpectraMax® MiniMax™) increasing the instruments flexibility. This highly sensitive instrument accommodates the budget and throughput needs of both small and large laboratories alike.

The SpectraMax® i3 Platform's base system features an integrated optical system which enables both top and bottom reads for 6-, 384- well microplates and launches with three broad detection modes: luminescence, absorbance, and fluorescence. The patented user-exchangeable cartridge design expands the system's detection capability making it highly versatile, and able to offer application options far exceeding those of standard readers.

Using a combination of a flash lamp for spectral flexibility and light emitting diodes (LEDs) for excitation power, Molecular Devices has developed the patent-pending Spectral Fusion™ Illumination to deliver wavelength flexibility whilst maximizing signal strength, ultimately increasing overall performance.

Data from the SpectraMax® i3 System is captured and analysed using Molecular Devices' proprietary, industry-leading SoftMax® Pro Software. The newly updated interface and Spectral Optimization Wizard simplifies the workflow and provides powerful data analysis features, eliminating the need for training on additional software. The SpectraMax® i3 System is also available for use in GMP and GLP labs when used with the SoftMax® Pro 6.3 GxP Microplate Data Compliance Software. This new user interface and powerful data analysis package simplifies the set-up of the SpectraMax® i3 platform, getting you to your results much faster!

SpectraMax® MiniMax™ Imaging Cytometer

When is the last time you inspected your cells and ran an assay on the same instrument? With the user-upgradable imaging cytometer option, turn your SpectraMax® i3 microplate reader into a cellular imager and unlock a new world of applications. 

The MiniMax™ Imaging Cytometer module adds first of its kind cellular imaging to a multi-mode detection platform, enabling fluorescence and bright field cellular imaging. Combining cellular imaging with microplate-based applications offers new ways for scientists to compress their workflows and increase efficiency. 

Key benefits include:

User Upgradeability:
Expand the 3-mode base system with additional application cartridges for FP, HTRF®, AlphaScreen® assays and cellular imaging. These user-installable cartridges prevent the need for system down time or service engineers. 

SpectraMax® MiniMax™ Imaging Cytometer:
Simplifies complex imaging workflows by visualising cell morphology changes on top of well-based intensity readings

Spectral Fusion™ Illumination:
Delivers high-powered full spectrum light source for increased fluorescence performance across the entire excitation range

Expanded Dynamic Range:
Sophisticated engineering delivers optimal sensitivity and maximises signal range 

Imagine the SpectraMax® i3 in your lab today and begin to realise what this system will bring to your research!

For more information on the SpectraMax® i3 and SpectraMax® MiniMax™ and to see a video of them in action CLICK HERE

Product SpectraMax® i3: When is the last time you inspected your cells and ran an assay on the same instrument?
Company Molecular Devices
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Molecular Devices
660 - 665 Eskdale Road Winnersh Triangle Wokingham Berkshire RG41 5TS

Tel: +44-118-944-8000
Fax: +44-118-944-8001
Email: infoboxeu@moldev.com



Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!